Balancing safety, efficacy and cost in drug development is challenging. Prodrugs offer potential solutions, but also introduce additional complexities, as Dave Elder explains.
The drug development and commercialisation processes are imperfect. The approved drug is the best possible combination of safety, efficacy, quality and cost factors.1 The balance between these competing factors changes depending on the nature of the therapeutic disorder – if the disease is life threatening then significant adverse events (AEs) are allowable;2 but typically, such black box warnings2 are not acceptable. Regulatory requirements are also continuously changing; requirements for drugs approved in the 1970s-80s are far less than seen today. This has significant impact on drug repositioning,3 eg, thalidomide is being re-positioned to treat leprosy and myeloma, but strict anti-pregnancy controls will be required.3
There are several formulation strategies available to address safety or efficacy deficiencies. If AEs are “cmax mediated” then blunting cmax using a controlled release formulation is an option.4 If there are safety concerns with respect to high levels of impurities, ie, N-nitrosamine drug substance-related impurities (NDSRIs) the drug can be re-formulated to include a nitrite scavenger and a pH modifying agent.5 Reduced clinical efficacy of low solubility drugs, eg, biopharmaceutics classification system BCS class II or IV drugs can often be addressed using either amorphous stabilised (eg, ritonavir6) or lipidic emulsion (eg, cyclosporine7) strategies – but stability is often an issue. Sometimes these formulation fixes are a short-term endeavour until a better molecule can be developed.
The role of prodrugs
Prodrugs are inactive versions of the parent drug, which have been chemically modified to enhance drug properties”
Prodrugs are inactive versions of the parent drug, which have been chemically modified to enhance physico-chemical, metabolic or biopharmaceutical drug properties. Prodrugs show enhanced performance (compared to the parent drug), which speeds up the process of drug development, saving time, money and effort.8 However, prodrugs are not a panacea. The increased complexity of the prodrug often negatively impacts on the product’s cost of goods (CoGs). The chemical stability of some of the simple ester and amide prodrugs can also be adversely impacted due to hydrolytic instability.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
Those prodrugs that are converted to the active drug pre-systemically, eg, fosamprenavir, may be able to use pre-existing safety data for the drug, eg, amprenavir, in support of their approval. In contrast, prodrugs that are absorbed as the prodrug may be considered for a BCS-based biowaiver.8 However, such prodrugs will likely require additional efficacy and safety data.9
The metabolic conversion of prodrugs to active drugs can vary among individuals, leading to inconsistent therapeutic outcomes.”
The metabolic conversion of prodrugs to active drugs can vary among individuals, leading to inconsistent therapeutic outcomes. Prodrugs can also show unexpected side effects or interactions with other medications.10-12
Different prodrugs, for the same therapeutic condition, can show fewer side effects than the marketed form, particularly if the AEs are cmax-mediated. Interestingly, there is a court case pending in California which alleges that a company’s decision to delay commercialisation of a different prodrug was negligent.13 The plaintiffs could assert a negligence claim based on the company’s “alleged decision to delay commercialisation of…tenofovir alafenamide fumarate (TAF), once it allegedly acquired actual knowledge that TAF is safer than, and equally effective [to], tenofovir disoproxil fumarate (TDF).”
However, studies14 have highlighted that the chemical and enzymatic stability of bis-alkyloxycarbonyloxymethyl prodrug esters candidates of tenofovir was the chief challenge. Of the four stable prodrug esters identified, two showed increased bioavailability relative to the free acid and one was selected for development.
A claim for superior safety can only typically be supported using Phase III clinical studies”
However, it isn’t possible at this early stage to screen for more complex toxicities, ie, TDF had black box labels for bone and kidney damage.12 A claim for superior safety can only typically be supported using Phase III clinical studies. Thus, despite many decades of research on different drug/prodrug forms, “choosing the ideal prodrug form remains a challenge which is often solved empirically.”13,14
About the author
Dave Elder, PhD, has worked in the pharmaceutical industry for 45 years for GSK, Syntex and Sterling. He is currently a CMC consultant with an interest in impurities and safety‑based limits. Dave is a member of the British Pharmacopoeia Expert Advisory Group, PCN (Pharmacy and Nomenclature) and a former member of RSC’s Analytical Division Council and JPAG (Joint Pharmaceutical Analysis Group).
References
Joshi HN. Drug development and imperfect design. Int J Pharm. 2007;343(1–2):1-3.
Hagan JB, Ender E, Divekar RD, et al. Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies. Mayo Clin Proc Innov Qual Outcomes. 2022 Feb;6(1):69–76.
Amare GG, Meharie BG, Belayneh YM. A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide. J Oncol Pharm Pract. 2021Apr;27(3):673-678.
Leppik IE, Hovinga CA. Extended-release antiepileptic drugs: A comparison of pharmacokinetic parameters relative to original immediate-release formulations. Epilepsia. 2013; 54(1):28–35.
Bayne A_CV, Misic Z, Stemmler RT, et al. N-nitrosamine Mitigation with Nitrite Scavengers in Oral Pharmaceutical Drug Products. J Pharm Sci. 2023;112(7):1794-1800.
Tambe S, Jain D, Meruva SK, et al. Recent Advances in Amorphous Solid Dispersions: Preformulation, Formulation Strategies, Technological Advancements and Characterization. Pharmaceutics. 2022Oct;14(10):2203.
Yocum DE, Allard S, Cohen SB, et al. Microemulsion formulation of cyclosporin (Sandimmun Neoral) vs Sandimmun: comparative safety, tolerability and efficacy in severe active rheumatoid arthritis. On behalf of the OLR 302 Study Group. Rheumatology (Oxford). 2000;39(2):156-64.
ICH M9 guideline on biopharmaceutics classification system-based biowaivers Step 5. 10 February 2020 EMA/CHMP/ICH/493213/2018 Committee for Medicinal Products for Human Use.
Markovic M, Ben-Shabat S, Dahan A. Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products. Pharmaceutics. 2020;12(11):1031.
Fagerholm U, Hellberg S, Alvarsson J, Spjuth O. Predicting Gastrointestinal Absorption of Prodrugs and their Drugs with the ANDROMEDA by Prosilico Software. [Internet] 2022. [cited 2023Jun] Available from: https://www.biorxiv.org/content/biorxiv/early/2022/11/26/2022.11.23.517725.full.pdf.
Kuhlmann IRB. Codeine, morphine, and metformin: Common aspects of drug transport, drugdrug interactions, and pharmacogenetics. Clin Pharmacol Pharm Environ Med. 2021. [cited 2023Jun] Available from: https://portal.findresearcher.sdu.dk/en/publications/codeine-morphine-and-metformin-common-aspects-of-drug-transport-d.
Agneshwar A, Wiesner J, Huynh T. Gilead Tenofovir Cases. Food Drug Law Institute. [Internet] 2024. [cited 2024Jun] Available from: https://www.fdli.org/.
Wiemar AJ. Metabolic Efficacy of Phosphate Prodrugs and the Remdesivir Paradigm. ACS Pharmacol. Sci. 2020;3:613−626.
Shaw JP, Sueoka CM, Oliyai R, et al. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)-propyl]adenine (PMPA) in dogs. Res. 1997;14:1824−1829.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.